Boston, Medtronic invest in MIS (minimally invasive) valve firm:
This article was originally published in Clinica
Executive Summary
Boston Scientific and Medtronic were among investors providing Fort Lee, New Jersey-based Percutaneous Valve Technologies with $14m. The two companies will each have a board representative at the company, which is developing a minimally invasive alternative to aortic valve replacement for aortic stenosis. Current treatment involves opening the chest, stopping the heart and placing the patient on a bypass machine. PVT is developing a device for placement under local anaesthesia in a cardiac catheterisation laboratory, which uses balloon-expandable stent technology and a bioprosthetic valve.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.